(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 129.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.91%.
Agios Pharmaceuticals's revenue in 2026 is $44,791,000.On average, 12 Wall Street analysts forecast AGIO's revenue for 2026 to be $6,561,470,126, with the lowest AGIO revenue forecast at $3,828,884,896, and the highest AGIO revenue forecast at $11,694,834,997. On average, 11 Wall Street analysts forecast AGIO's revenue for 2027 to be $14,988,982,236, with the lowest AGIO revenue forecast at $7,314,884,577, and the highest AGIO revenue forecast at $25,532,702,584.
In 2028, AGIO is forecast to generate $34,565,512,063 in revenue, with the lowest revenue forecast at $22,984,972,138 and the highest revenue forecast at $51,249,093,676.